Results 241 to 250 of about 1,854,346 (342)

Equilibrium Implications of Social Utility and Reference Dependence

, 2013
Kangkang Wang
openalex   +2 more sources

Measurement of Percentage Depth-Dose Distributions in Clinical Dosimetry: Conventional Techniques and Emerging Sensor Technologies. [PDF]

Sensors (Basel)
Petringa G, Raffaele L, Cuttone G, Guarrera M, Kurmanova A, Catalano R, Cirrone GAP.   +6 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Nav1.8 Variant I206M as a Latent Susceptibility Factor in Postaxotomy Ocular Pain. [PDF]

Neurol Genet
Ghovanloo MR, Effraim PR, Tyagi S, Aldrich AM, Yuan JH, Schulman BR, Jacobs DS, Dib-Hajj SD, Waxman SG.   +8 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Mental health of caregivers for people with dementia and cerebral palsy as a key determinant of caregiver burden: a multivariable analysis. [PDF]

Front Public Health
Sánchez-Gil A, Calleja-Caballero A, Pérez-Robledo F, Martín-Sánchez C, Rodríguez-Lorenzo M, Martínez-Romo M, Pérez-Saez E, Rodríguez-Muñoz PM, Rivera-Picón C, Perez J, Sánchez-González JL.   +10 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Study and Mathematical Model of the Chemical Composition and Structure of the Compound Sb₂(S_1-xSe_x)₃ Based on a Correlation of Data Obtained Through XRD and XPS Characterization. [PDF]

Materials (Basel)
López-García M, Chalé-Lara F, Rodríguez-González E, González-Castillo JR, López-Oyama AB.   +4 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians: 2008 Update

, 2009

openalex   +1 more source